^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Kinase inhibitor

    Related drugs:
    20d
    Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors. (PubMed, Acta Pharm Sin B)
    Furthermore, in PDX model established using AML cells from Gilteritinib-resistant patients, the degrader showed significantly superior therapeutic efficacy compared to the combination treatment of Gilteritinib and Imatinib. As a candidate drug molecule, this degrader exhibits promising potential for clinical translation.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    |
    imatinib • Xospata (gilteritinib)
    20d
    Src Family Kinase Inhibitors Bosutinib and Dasatinib Enhance ATRA-induced Differentiation of NB4 Leukemia Cells. (PubMed, Anticancer Res)
    Clinically available SFK inhibitors, particularly dasatinib, synergistically enhance ATRA-induced myeloid differentiation of NB4 APL cells and are more effective than the conventional ATRA plus ATO combination in this in vitro model. These findings support further preclinical and clinical evaluation of SFK inhibitor plus ATRA combinations as differentiation-oriented strategies and potential alternatives or complements to ATO-containing regimens in APL.
    Journal
    |
    ITGAM (Integrin, alpha M)
    |
    dasatinib • bosutinib • arsenic trioxide
    21d
    Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2027
    Trial completion date
    |
    berzosertib (M6620) • topotecan
    1m
    MISTIK: Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies (clinicaltrials.gov)
    P=N/A, N=160, Completed, Rennes University Hospital | Recruiting --> Completed | N=360 --> 160
    Trial completion • Enrollment change
    2ms
    Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemia. (PubMed, iScience)
    Comparing benign hematologic tissues with CML samples revealed about 90 CML-specific peptides that became more prominent after SFK or JNK inhibition. Overall, this work provides a quantitative, multi-omic framework to rationally combine kinase inhibitors with immunotherapy to boost antigen visibility and antileukemic immunity.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    2ms
    FAK Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=75, Not yet recruiting, InxMed (Shanghai) Co., Ltd.
    New P1 trial
    2ms
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=92, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting | N=30 --> 92
    Enrollment open • Enrollment change • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV
    3ms
    LUNG-RESIST: Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients (clinicaltrials.gov)
    P=N/A, N=80, Active, not recruiting, University Hospital, Toulouse | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    3ms
    OMX-0407-101: A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically (clinicaltrials.gov)
    P1/2, N=68, Terminated, iOmx Therapeutics AG | N=188 --> 68 | Active, not recruiting --> Terminated; Study terminated as part of strategic considerations and not based on safety concerns.
    Enrollment change • Trial termination
    |
    OMX-0407
    3ms
    TQB3616-I-0001: A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown status --> Completed | N=30 --> 40
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Saitanxin (culmerciclib)
    3ms
    RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=159, Completed, EIP Pharma Inc | Trial primary completion date: Oct 2024 --> May 2025
    Trial primary completion date
    4ms
    CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to inhibit oxidative stress and ferroptosis. (PubMed, Free Radic Biol Med)
    Furthermore, CDDO-Me did not compromise the antitumor efficacy of DOX/LAP in breast cancer cells. CDDO-Me protects against DOX/LAP-induced cardiotoxicity by stabilizing GPX4 and inhibiting ferroptosis, offering a promising therapeutic strategy that preserves cardiac function without interfering with chemotherapy.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    lapatinib • doxorubicin hydrochloride